A panel of de novo designed intracellular protein binders that target conserved functional regions of MYC with nanomolar affinity, remodel MYC complexes and interaction networks in cells, suppress proliferation across MYC-dependent cancer models, and are depleted from orthotopic pancreatic tumors in vivo are developed.
N. McNamara-Bordewick, Ke-Jia Wu, Yu-Long Su et al.· bioRxiv· 0 citations
Findings show that muscle and adipose wasting have distinct relationships with tumor-intrinsic MYC in PDAC cachexia, indicating that muscle and adipose wasting can be uncoupled in PDAC cachexia.
Ting-Ting Zhang, Fa-Ming Zhao, Xiao-Yan Wang et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) and poor prognosis. Although major histocompatibility complex class II (MHC-II) is typically expressed by professional antigen-presenting cells, its regulation and significance in malignant PDAC cells remain un...
Can-Ping Chen, Yi Zhang, Xi Li et al.· Cancer immunology research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) disease progression involves complex cell state transitions in both malignant and non-malignant populations within the tumor microenvironment. To uncover PDAC cell states and epigenetic features associated with clinical outcome, we profiled 40 tumor samples (33 primary tumors a...
Kevin Hawthorne, Motoyuki Tsuda, Jenny Eng et al.· Cancer Research· 0 citations
Overall, it is found that the post-transcriptional regulator HuR facilitates immune evasion in PDAC by constraining T-cell function, identifying HuR blockade as a promising therapeutic strategy in combination with immunotherapies.
Yi-Fei Guo, Jennifer M. Finan, Alexandra Q. Bartlett et al.· Cancer immunology research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.